Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Apolipoprotein E (APOE) Peptide

APOE Reactivity: Human Host: Synthetic BP, IHC, WB
Catalog No. ABIN973323

Quick Overview for Apolipoprotein E (APOE) Peptide (ABIN973323)

Target

APOE (Apolipoprotein E (APOE))

Origin

Human

Source

  • 6
Synthetic

Application

Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
  • Characteristics

    This is a synthetic peptide designed for use in combination with anti-APOE antibody (Catalog #: ARP54283_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.

    Purification

    Purified
  • Application Notes

    Each Investigator should determine their own optimal working dilution for specific applications.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Concentration

    1 mg/mL

    Buffer

    Final peptide concentration is 1 mg/mL in PBS.

    Handling Advice

    Avoid repeated freeze-thaw cycles.

    Storage

    -20 °C

    Storage Comment

    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target

    APOE (Apolipoprotein E (APOE))

    Background

    Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.

    Alias Symbols: AD2, MGC1571, apoprotein, LPG, LDLCQ5

    Protein Interaction Partner: CNTF,CNTF,HCVgp1,A2M,ALB,APOE,APP,CNTF,CTSB,LDLR,LRP1,LRP2,LRP8,MAP2,MAPT,NEFM,PLTP,PRNP,SCARB1,VLDLR,A2M,LRP2,LRP8,MAPT,NEFM,PLTP

    Protein Size: 317

    Molecular Weight

    34 kDa

    Gene ID

    348

    NCBI Accession

    NM_000041, NP_000032

    UniProt

    P02649
You are here:
Chat with us!